Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

most likely drawn from the glucagon-like peptide 1 class of drugs. As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...